Title

Underuse of pregnancy testing for women prescribed teratogenic medications in the emergency department.

Year of Publication

2015

Number of Pages

192-6

Date Published

02/2015

ISSN Number

1553-2712

Abstract

<p><strong>OBJECTIVES: </strong>The objectives were to estimate the frequency of pregnancy testing in emergency department (ED) visits by reproductive-aged women administered or prescribed teratogenic medications (Food and Drug Administration categories D or X) and to determine factors associated with nonreceipt of a pregnancy test.</p>

<p><strong>METHODS: </strong>This was a retrospective cross-sectional study using 2005 through 2009 National Hospital Ambulatory Medical Care Survey data of ED visits by females ages 14 to 40&nbsp;years. The number of visits was estimated where teratogenic medications were administered or prescribed and pregnancy testing was not conducted. The association of demographic and clinical factors with nonreceipt of pregnancy testing was assessed using multivariable logistic regression.</p>

<p><strong>RESULTS: </strong>Of 39,859 sampled visits, representing an estimated 141.0 million ED visits by reproductive-aged females nationwide, 10.1 million (95% confidence interval [CI]&nbsp;=&nbsp;8.9 to 11.3 million) estimated visits were associated with administration or prescription of teratogenic medications. Of these, 22.0% (95% CI&nbsp;=&nbsp;19.8% to 24.2%) underwent pregnancy testing. The most frequent teratogenic medications administered without pregnancy testing were benzodiazepines (52.2%; 95% CI&nbsp;=&nbsp;31.1% to 72.7%), antibiotics (10.7%; 95% CI&nbsp;=&nbsp;5.0% to 16.3%), and antiepileptics (7.7%; 95% CI&nbsp;=&nbsp;0.12% to 15.5%). The most common diagnoses associated with teratogenic drug prescription without pregnancy testing were psychiatric (16.1%; 95% CI&nbsp;=&nbsp;13.6% to 18.6%), musculoskeletal (12.7%; 95% CI&nbsp;=&nbsp;10.8% to 14.5%), and cardiac (9.5%; 95% CI&nbsp;=&nbsp;7.6% to 11.3%). In multivariable analyses, visits by older (adjusted odds ratio [AOR]&nbsp;= 0.57, 95% CI&nbsp;=&nbsp;0.42 to 0.79), non-Hispanic white females (AOR&nbsp;= 0.71; 95% CI&nbsp;=&nbsp;0.54 to 0.93); visits in the Northeast region (AOR&nbsp;= 0.60; 95% CI&nbsp;=&nbsp;0.42 to 0.86); and visits during which teratogenic medications were administered in the ED only (AOR&nbsp;= 0.74; 95% CI&nbsp;=&nbsp;0.57 to 0.97) compared to prescribed at discharge only were less likely to have pregnancy testing.</p>

<p><strong>CONCLUSIONS: </strong>A minority of ED visits by reproductive-aged women included pregnancy testing when patients were prescribed category D or X medications. Interventions are needed to ensure that pregnancy testing occurs before women are prescribed potentially teratogenic medications, as a preventable cause of infant morbidity.</p>

DOI

10.1111/acem.12578

Alternate Title

Acad Emerg Med

PMID

25639672

WATCH THIS PAGE

Subscription is not available for this page.